Login / Signup

Anti-CD19 CAR T as a feasible therapy for refractory/relapsed mixed phenotype acute leukemia patients.

Xiangqun LiKylan ChenHailong ZhangXian ZhangJunfang YangJing LiuJianwei ZhengFei DongYongbo ZhuJiao YuHaihong ZhangKai-Yan LiuBo Chen
Published in: Pediatric blood & cancer (2022)
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • acute lymphoblastic leukemia
  • peritoneal dialysis
  • diffuse large b cell lymphoma
  • patient reported outcomes